Amgen today announced that the U.S. Food and Drug Administration has approved LUMAKRAS ™ for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS has received accelerated approval based on overall response rate and duration of response . Continued ...